Table 1 General clinical characteristics
Training cohort (n = 551) | Validation cohort (n = 237) | P-value | |||
|---|---|---|---|---|---|
LNM | non-LNM | LNM | non-LNM | ||
Gender | 0.662 | ||||
Male (%) | 135(24.50%) | 226(41.02%) | 54(22.78%) | 84(35.44%) | |
female (%) | 77(13.97%) | 113(20.51%) | 37(15.61%) | 62(26.16%) | |
Age | 63.18 ± 10.61 | 63.13 ± 11.45 | 62.42 ± 14.03 | 64.55 ± 12.02 | 0.481 |
Diameter (mean ± SD, cm) | 3.95 ± 1.44 | 3.77 ± 1.58 | 3.85 ± 1.10 | 3.58 ± 1.45 | 0.048 |
Location | 0.262 | ||||
low (%) | 46(8.35%) | 80(14.52%) | 17(7.11%) | 38(16.03%) | |
medium (%) | 80(14.52%) | 143(25.95%) | 34(14.35%) | 49(20.68%) | |
high (%) | 86(15.61%) | 116(21.05%) | 40(16.88%) | 59(24.89%) | |
PNI (%) | 93(16.88%) | 71(12.89%) | 36(15.19%) | 34(14.35%) | 0.000 |
EMVI (%) | 152(27.59%) | 69(12.52%) | 67(28.27%) | 41(17.30%) | 0.000 |
MSI (%) | 27(4.90%) | 47(8.53%) | 10(4.22%) | 13(5.49%) | 0.947 |
CEA (mean ± SD,µg/L) | 60.17 ± 416.98 | 6.62 ± 12.92 | 22.87 ± 49.47 | 5.35 ± 9.98 | 0.034 |
CA19−9 (mean ± SD,U/mL) | 61.86 ± 205.40 | 20.20 ± 90.44 | 36.30 ± 79.22 | 22.40 ± 74.61 | 0.002 |
Diabetes (%) | 22(3.99%) | 41(7.44%) | 14(5.91%) | 15(6.33%) | 0.887 |
Hypertension (%) | 67(12.16%) | 135(24.50%) | 36(15.19%) | 44(18.57%) | 0.406 |
Smoking (%) | 40(7.26%) | 73(13.25%) | 17(7.17%) | 25(10.55%) | 0.632 |
Drinking (%) | 27(4.90%) | 58(10.53%) | 11(4.64%) | 24(10.13%) | 0.097 |